Business

Concerts drive travel choices, 62% of India's Gen Z pla...

Experience-led tourism is gaining momentum among India's Gen Z, as a survey done...

Gold price today: How much 22K, 24K gold cost in Delhi,...

Gold prices experienced a slight dip on Wednesday as investors engaged in profit...

Robust economy! India's GDP growth projected at 7.4% in...

​India's economy will grow at a robust 7.4% in the financial year 2025-26, accor...

Why did Rain Industries rally 50% over the last month?

Synopsis: Rain Industries, engaged in the production of carbon, advanced materia...

Aster DM and Quality Care Merger: Can The New Healthcar...

Synopsis: Aster DM Healthcare and Quality Care merger aims to reshape India’s ho...

Can Nifty 50 touch 28,000 this year? Here’s what Bernst...

Synopsis: As market conditions evolve, let’s explore whether the Nifty will touc...

Multibagger stock held by Ajay Devgan soars 5% after si...

Synopsis: Panorama Studios International jumped sharply after signing a massive ...

Block Deal: Pharma stock jumps 8% after 13 Lakh shares ...

Synopsis: Bliss GVS Pharma shares surged 8% following a block deal of 13.26 lakh...

2025 IPO giants: LG, Tata Capital and other top IPOs th...

Synopsis: In 2025 there were 377 IPOs that were issued in the Indian Stock marke...

Dividend Update: RBI releases new draft norms for bank ...

Synopsis: RBI proposes capping bank dividends at 75% of adjusted PAT, tightening...

Yash Highvoltage and 3 other stocks in focus after prom...

Synopsis: In this article, we take a look at the list of stocks in which promote...

Midcap stock jumps after launching 3 new cancer treatme...

Synopsis: Biocon Limited shares rose 2% as it added three oncology biosimilars, ...

1:10 Stock Split: Smallcap stock jumps 3% after receivi...

SYNOPSIS: Sri Adhikari Brothers approved a 1:10 stock split, promoter loans up t...

ACE Unpacked: Market Dominance, Cyclical Headwinds, and...

Synopsis: ACE’s ~40% discount decoded: leadership strength, cyclical headwinds, ...

Pharma Stock Falls 4% After USFDA Flags Issues at Its K...

Synopsis: Cipla is in focus after the US FDA raised issues regarding a significa...

banner
banner